NCT01987765

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 847 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in clinical practice.

Conditions

• Conjunctivitis, Allergic

Interventions

Type	Name	Description
DRUG	Relestat Ophthalmic Solution 0.05%	Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.

Timeline

• Start date: 2009-01-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2013-11-19
• Last updated: 2014-04-29
• Results posted: 2014-04-29

Locations

1 site across 1 country: South Korea